XFOR Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -6552.86% compared to X4 Pharmaceuticals's net margin of 32.59%. X4 Pharmaceuticals's return on equity of -30.6% beat Eli Lilly and's return on equity of 80.24%.

X4 Pharmaceuticals has a consensus price target of $3.13, signalling upside risk potential of 818.85%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.85%. Given that X4 Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe X4 Pharmaceuticals is more attractive than Eli Lilly and.

X4 Pharmaceuticals has a beta of 0.387, which suggesting that the stock is 61.26% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

X4 Pharmaceuticals quarterly revenues are $560K, which are smaller than Eli Lilly and quarterly revenues of $13.5B. X4 Pharmaceuticals's net income of -$36.7M is lower than Eli Lilly and's net income of $4.4B. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while Eli Lilly and's PE ratio is 70.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 16.51x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -6552.86% compared to X4 Pharmaceuticals's net margin of -49.65%. X4 Pharmaceuticals's return on equity of -30.6% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

X4 Pharmaceuticals has a consensus price target of $3.13, signalling upside risk potential of 818.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.92%. Given that X4 Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe X4 Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

X4 Pharmaceuticals has a beta of 0.387, which suggesting that the stock is 61.26% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

X4 Pharmaceuticals quarterly revenues are $560K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. X4 Pharmaceuticals's net income of -$36.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Prestige Consumer Healthcare has a net margin of -6552.86% compared to X4 Pharmaceuticals's net margin of 21.02%. X4 Pharmaceuticals's return on equity of -30.6% beat Prestige Consumer Healthcare's return on equity of 12.65%.

X4 Pharmaceuticals has a consensus price target of $3.13, signalling upside risk potential of 818.85%. On the other hand Prestige Consumer Healthcare has an analysts' consensus of $89.14 which suggests that it could grow by 6.22%. Given that X4 Pharmaceuticals has higher upside potential than Prestige Consumer Healthcare, analysts believe X4 Pharmaceuticals is more attractive than Prestige Consumer Healthcare.

X4 Pharmaceuticals has a beta of 0.387, which suggesting that the stock is 61.26% less volatile than S&P 500. In comparison Prestige Consumer Healthcare has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.291%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prestige Consumer Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. Prestige Consumer Healthcare pays out -- of its earnings as a dividend.

X4 Pharmaceuticals quarterly revenues are $560K, which are smaller than Prestige Consumer Healthcare quarterly revenues of $290.3M. X4 Pharmaceuticals's net income of -$36.7M is lower than Prestige Consumer Healthcare's net income of $61M. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while Prestige Consumer Healthcare's PE ratio is 19.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 3.76x for Prestige Consumer Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -6552.86% compared to X4 Pharmaceuticals's net margin of -2357.27%. X4 Pharmaceuticals's return on equity of -30.6% beat Palatin Technologies's return on equity of --.

X4 Pharmaceuticals has a consensus price target of $3.13, signalling upside risk potential of 818.85%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 780.5%. Given that X4 Pharmaceuticals has higher upside potential than Palatin Technologies, analysts believe X4 Pharmaceuticals is more attractive than Palatin Technologies.

X4 Pharmaceuticals has a beta of 0.387, which suggesting that the stock is 61.26% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

X4 Pharmaceuticals quarterly revenues are $560K, which are larger than Palatin Technologies quarterly revenues of $350K. X4 Pharmaceuticals's net income of -$36.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.